Succeeding In Low Molecular Weight Heparin Market : Three Tips, Five Trends
Increasing inclination of research institutes towards increasing application of LMWH in various new treatment is expected to grow the demand of LMWH, in near future. For instance, American University of Beirut Medical Centre sponsored the study of a drug, bemiparin sodium (a form of LMWH), which is in phase 4 and helps to improve pregnancy outcomes in patients with recurrent implantation failure undergoing IVF/ ICSI treatment. Furthermore, key players in the market are collaborating with hospitals to strengthen their product portfolio. Get More Insights (at) https://www.coherentmarketinsights.com/market-insight/low-molecular-weight-heparin-market-1491
Increasing inclination of research institutes towards increasing application of LMWH in various new treatment is expected to grow the demand of LMWH, in near future. For instance, American University of Beirut Medical Centre sponsored the study of a drug, bemiparin sodium (a form of LMWH), which is in phase 4 and helps to improve pregnancy outcomes in patients with recurrent implantation failure undergoing IVF/ ICSI treatment. Furthermore, key players in the market are collaborating with hospitals to strengthen their product portfolio.
Get More Insights (at) https://www.coherentmarketinsights.com/market-insight/low-molecular-weight-heparin-market-1491
Create successful ePaper yourself
Turn your PDF publications into a flip-book with our unique Google optimized e-Paper software.
LOW<br />
MOLECULAR<br />
WEIGHT HEPARIN<br />
MARKET<br />
<strong>Market</strong> Size (2017)<br />
US$ 2.88 BN<br />
CAGR (2018 -<br />
2026)<br />
6.7%<br />
© Coherent <strong>Market</strong> <strong>In</strong>sights. All Rights Reserved
Segmentation (Scope)<br />
By Drug<br />
‣ Enoxaparin<br />
‣ Dalteparin<br />
‣ Nadroparin<br />
‣ Bemiparin<br />
‣ Tinzaparin<br />
‣ Others<br />
By Application<br />
‣ Deep Vein Thrombosis<br />
‣ Acute Coronary Syndrome (ACS)<br />
‣ Pulmonary Embolism<br />
‣ Atrial Fibrillation<br />
By Packaging<br />
‣ Multi Vials<br />
‣ Prefilled Syringes<br />
By End User<br />
‣ Hospitals<br />
• Private<br />
• Public<br />
‣ Clinics<br />
‣ Other End Users<br />
© Coherent © Coherent <strong>Market</strong> <strong>Market</strong> <strong>In</strong>sights. All All Rights Rights Reserved Reserved
Major Drivers<br />
<br />
<br />
<br />
Advantages of <strong>Low</strong> <strong>Molecular</strong> <strong>Weight</strong> <strong>Heparin</strong> over<br />
Unfractionated <strong>Heparin</strong><br />
<strong>In</strong>creasing Demand for <strong>Low</strong> <strong>Molecular</strong> <strong>Weight</strong> <strong>Heparin</strong><br />
<strong>In</strong>troduction of Biosimilar LMWH Anticoagulants<br />
© Coherent © Coherent <strong>Market</strong> <strong>Market</strong> <strong>In</strong>sights. All All Rights Rights Reserved Reserved
NORTH<br />
AMERICA<br />
<strong>Market</strong> Size (2017)<br />
US$ 853.25 MN<br />
CAGR<br />
7.4%<br />
ASIA<br />
PACIFIC<br />
<strong>Market</strong> Size (2017)<br />
US$ 527.5 MN<br />
CAGR<br />
6.1%<br />
Major Drivers<br />
<strong>In</strong>creasing number of clinical trials conducted<br />
in the region<br />
<strong>In</strong>creasing venous thromboembolism (VTE)<br />
and atrial fibrillation<br />
Major Drivers<br />
<strong>In</strong>creasing prevalence of venous thromboembolism<br />
(VTE) in the region<br />
<strong>In</strong>creasing focus of manufacturers<br />
© Coherent © Coherent <strong>Market</strong> <strong>Market</strong> <strong>In</strong>sights. All All Rights Rights Reserved Reserved
1<br />
Pfizer, <strong>In</strong>c.<br />
2<br />
LEO Pharma A/S<br />
3<br />
Sanofi S.A.<br />
Major<br />
Players<br />
4<br />
5<br />
6<br />
7<br />
Teva Pharmaceutical <strong>In</strong>dustries ltd.<br />
Amphastar Pharmaceuticals <strong>In</strong>c.<br />
Aspen Pharmacare Holdings Healthcare<br />
Laboratorios Farmaceuticos ROVI SA<br />
8<br />
Changzhou Qianhong Biopharma<br />
9<br />
<strong>In</strong>trapharm Laboratories<br />
10<br />
Abbott Laboratories AG<br />
© Coherent © Coherent <strong>Market</strong> <strong>Market</strong> <strong>In</strong>sights. All All Rights Rights Reserved Reserved
Global <strong>Low</strong> <strong>Molecular</strong> <strong>Weight</strong> <strong>Heparin</strong> <strong>Market</strong><br />
Share (%), By Application, 2018 and 2026<br />
2018 2026<br />
Deep Vein<br />
Thrombosis<br />
Acute Coronary<br />
Syndrome<br />
Pulmonary<br />
Embolism<br />
Atrial<br />
Fibrillation<br />
Deep Vein<br />
Thrombosis<br />
Acute Coronary<br />
Syndrome<br />
Pulmonary<br />
Embolism<br />
Atrial<br />
Fibrillation<br />
© Coherent © Coherent <strong>Market</strong> <strong>Market</strong> <strong>In</strong>sights. All All Rights Rights Reserved Reserved
Change language